Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Amortization of Deferred Charges (2016 - 2018)

Historic Amortization of Deferred Charges for Avalo Therapeutics (AVTX) over the last 5 years, with Q4 2018 value amounting to -$24342.0.

  • Avalo Therapeutics' Amortization of Deferred Charges fell 243410000.0% to -$24342.0 in Q4 2018 from the same period last year, while for Sep 2019 it was -$24342.0, marking a year-over-year decrease of 10743.9%. This contributed to the annual value of $302882.0 for FY2018, which is 138734.04% up from last year.
  • Per Avalo Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$24342.0 for Q4 2018, which was down 243410000.0% from -$24342.0 recorded in Q3 2018.
  • Over the past 5 years, Avalo Therapeutics' Amortization of Deferred Charges peaked at $246115.0 during Q2 2018, and registered a low of -$24342.0 during Q3 2018.
  • Its 5-year average for Amortization of Deferred Charges is $48444.5, with a median of $36946.0 in 2016.
  • Data for Avalo Therapeutics' Amortization of Deferred Charges shows a peak YoY increase of 299073.21% (in 2018) and a maximum YoY decrease of 243410000.0% (in 2018) over the last 5 years.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Amortization of Deferred Charges stood at $44292.0 in 2014, then surged by 100.91% to $88989.0 in 2015, then plummeted by 68.34% to $28174.0 in 2016, then crashed by 100.0% to -$1.0 in 2017, then tumbled by 2434100.0% to -$24342.0 in 2018.
  • Its last three reported values are -$24342.0 in Q4 2018, -$24342.0 for Q3 2018, and $246115.0 during Q2 2018.